You just read:

Aptinyx Receives FDA Fast Track Designation for Development of NYX-2925 as Treatment for Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

News provided by

Aptinyx Inc.

13 Sep, 2016, 08:00 ET